Drugs / BCMA CAR-NK 92 cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03940833 | May 2019 → May 2021 | plasma cell myeloma | Asclepius Technology Company Group (Suzhou) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCMA CAR-NK 92 cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03940833 ↗ |
| Action | Deplete | “The CAR enables the NK-92 cells to recognize and kill the MM cells by targeting of BCMA, a protein expressed of the surface of the malignant plasma cells in MM patients.” NCT03940833 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor (CAR) immune cell therapy” PMID 34471234 ↗ Sep 2021 |
| Route | Intravenous | “intravenous injection of the double-modified NK cells” PMID 34471234 ↗ Sep 2021 |